Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 May 11;11(1):10037.
doi: 10.1038/s41598-021-89490-z.

A systematic review and meta-analysis of angiotensin-converting enzyme inhibitor use and psoriasis incidence

Gonjin Song  1 , Ji Yea Kim  1 , Ha Young Yoon  1 , Jeong Yee  1 , Hye Sun Gwak  2
Affiliations
Meta-Analysis

A systematic review and meta-analysis of angiotensin-converting enzyme inhibitor use and psoriasis incidence

Gonjin Song et al. Sci Rep. .

Abstract

Although a considerable volume of data supporting induction or aggravation of psoriasis because of angiotensin-converting enzyme (ACE) inhibitor use exists, it remains insufficient for definitive conclusions. Therefore, we aimed to evaluate the association between ACE inhibitor use and psoriasis incidence through a systematic literature review and meta-analysis. We searched for qualifying studies across PubMed, Web of Science, and Embase. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the association between ACE inhibitor use and psoriasis incidence. Eight studies with a total of 54,509 patients with a psoriasis diagnosis were included in this meta-analysis. The pooled OR for psoriasis incidence among ACE inhibitor users was 1.52 (95% CI, 1.16-2.00) compared to that among non-users. From subgroup analysis by continent, the OR for ACE inhibitor users versus non-users was 2.37 (95% CI 1.28-4.37) in Asia. Per the subgroup analysis by climate, the OR for ACE inhibitor users vs non-users in dry climate was 3.45 (95% CI: 2.05-5.79) vs 1.32 (95% CI 1.01-1.73) in temperate climate. Our results reveal a significant association between ACE inhibitor use and psoriasis incidence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flow diagram of the study selection process.
Figure 2
Figure 2
Forest plot to compare psoriasis risk among ACE inhibitor users vs non-users.
Figure 3
Figure 3
Forest plots to compare psoriasis risk among ACE inhibitor users versus non-users by continent. (a) Asia. (b) Europe.
Figure 4
Figure 4
Forest plots to compare psoriasis risk among ACE inhibitor users verrsus non-users by climate. (a) Dry. (b) Temperate.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stavropoulos PG, Kostakis PG, Papakonstantinou AM, Panagiotopoulos A, Petridis AD. Coexistence of psoriasis and pemphigus after enalapril intake. Dermatology. 2003;207:336–337. doi: 10.1159/000073106. - DOI - PubMed
    1. Izzo JL, Jr, Weir MR. Angiotensin-converting enzyme inhibitors. J. Clin. Hypertens. (Greenwich). 2011;13:667–675. doi: 10.1111/j.1751-7176.2011.00508.x. - DOI - PMC - PubMed
    1. Thakor P, et al. Ramipril-induced generalized pustular psoriasis: case report and literature review. Am. J. Ther. 2010;17:92–95. doi: 10.1097/MJT.0b013e31818f9e99. - DOI - PubMed
    1. Wolf R, Tamir A, Brenner S. Psoriasis related to angiotensin-converting enzyme inhibitors. Dermatologica. 1990;181:51–53. doi: 10.1159/000247861. - DOI - PubMed
    1. Gilleaudeau P, Vallat VP, Carter DM, Gottlieb AB. Angiotensin-converting enzyme inhibitors as possible exacerbating drugs in psoriasis. J. Am. Acad. Dermatol. 1993;28:490–492. doi: 10.1016/S0190-9622(08)81761-6. - DOI - PubMed

MeSH terms

Substances